nivolumab + oxaliplatin

Nivolumab + oxaliplatin is a combination regimen used primarily in the first-line treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Nivolumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing tumor cells. This combination is typically administered with additional agents such as fluoropyrimidines (e.g., capecitabine or fluorouracil) as part of regimens like FOLFOX or CapeOX. The combination has demonstrated improved overall survival compared to chemotherapy alone in large phase 3 trials such as CheckMate-649[1][4][5][7].

Brand names

Opdivo

Other names

oxaliplatin and nivolumaboxaliplatin plus nivolumab